Back to Browse Journals » OncoTargets and Therapy » Volume 3

First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab

Authors Carmen Diana Schweighofer, Clemens-Martin Wendtner

Published Date March 2010 Volume 2010:3 Pages 53—67

DOI http://dx.doi.org/10.2147/OTT.S3099

Published 30 March 2010

Carmen Diana Schweighofer1, Clemens-Martin Wendtner2

1Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA; 2Department of Internal Medicine I, University of Cologne, Cologne, Germany

Abstract: The CD52-targeting antibody alemtuzumab is established in clinical practice with convincing activity in relapsed and refractory chronic lymphocytic leukemia (CLL), particularly in patients with high-risk features and adverse prognosis. In the CAM307 study alemtuzumab was tested and finally approved as a first-line single agent, even though the hurdle with chlorambucil as the contender was not set very high. Within clinical trials, the drug demonstrated an excellent ability to eliminate minimal residual disease in blood and bone marrow, which has been correlated with a corresponding survival advantage in patients. However, in the maintenance setting, infectious complications due to severe T cell suppression have been highlighted and do not allow clinicans to use alemtuzumab outside of clinical trials. This review discusses potential therapeutic niches and future applications of alemtuzumab with a focus on CLL front-line treatment.
Keywords: CLL, alemtuzumab, Campath, front-line, first-line treatment

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Photoactive TiO2 antibacterial coating on surgical external fixation pins for clinical application

Villatte G, Massard C, Descamps S, Sibaud Y, Forestier C, Awitor KO

International Journal of Nanomedicine 2015, 10:3367-3375

Published Date: 6 May 2015

In vivo enhancement of anticancer therapy using bare or chemotherapeutic drug-bearing nanodiamond particles

Li Y, Tong Y, Cao R, Tian Z, Yang B, Yang P

International Journal of Nanomedicine 2014, 9:1065-1082

Published Date: 21 February 2014

Vincristine sulfate liposomal injection for acute lymphoblastic leukemia

Soosay Raj TA, Smith AM, Moore AS

International Journal of Nanomedicine 2013, 8:4361-4369

Published Date: 6 November 2013

Letter to the editor

Ralla B, Holtmann C, Geerling G

Clinical Ophthalmology 2013, 7:243-246

Published Date: 5 February 2013

Composite scaffolds of mesoporous bioactive glass and polyamide for bone repair

Su J, Cao L, Yu B, Song S, Liu X, Wang Z, Li M

International Journal of Nanomedicine 2012, 7:2547-2555

Published Date: 21 May 2012

Reduced exercise capacity in persons with Down syndrome: cause, effect, and management

Goncalo V Mendonca, Fernando D Pereira1 Bo Fernhall

Therapeutics and Clinical Risk Management 2010, 6:601-610

Published Date: 8 December 2010

Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery

Yin-Ku Lin, Zih-Rou Huang, Rou-Zi Zhuo, et al

International Journal of Nanomedicine 2010, 5:117-128

Published Date: 25 February 2010